Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.

Abstract

Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension(EH). Patients with mild-to-moderate EH, selected at 44 sites in China from September 9, 2016, to December 7, 2018, were administered 240mg allisartan isoproxil daily for 4 weeks. Patients with controlled blood pressure(BP) continued monotherapy for 8 weeks, others were randomly assigned (1:1) to A + D group (allisartan isoproxil 240mg + indapamide 1.5mg) or A + C group (allisartan isoproxil + amlodipine besylate 5mg) for 8 weeks. BP were measured at week 4, 8 and 12. 2126 patients were included. After 12 weeks of treatment, systolic blood pressure(SBP) and diastolic blood pressure(DBP) decreased by 19.24 ±12.02 and 10.63 ±8.89 mmHg, respectively, and the overall BP control rate was 78.56%. The sitting blood pressures (SBP/DBP) decreased by 19.12 ±11.71/10.84 ±8.73 mmHg in patients with 12 weeks allisartan isoproxil monotherapy (both p < 0.0001). The BP reductions and control rates were comparable between A + D and A + C groups. 48 patients with monotherapy-controlled BP underwent ambulatory blood pressure monitoring, with a mean decrease in ambulatory blood pressure of 10.04 ±10.87/5.50 ±8.07 mmHg after 12 weeks of treatment, and consistent reductions between day and night. SBP and DBP had trough-to-peak ratios of 64.64% and 62.63% and smoothness indices of 3.82 and 2.92, respectively. An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.